How Is AI Used in Healthcare and Health Innovation?

Artificial Intelligence (AI) is a concept about which we have been aware for some time. It has been a popular topic of speculation in science fiction for centuries, but now we are closer than ever to living the fiction. The breakneck pace of tech innovation globally has seen recent breakthroughs in machine learning, and ‘intelligent’ algorithms have already been made available to consumers.

A tech revolution is at hand, and all sectors will see profound shifts as a result – none more, perhaps, than healthcare. Healthcare innovation is nothing short of vital, and AI could be the solution for many of the UK’s NHS issues. But how, exactly?

Improving Diagnostics

One of the leading areas in which Ai is seeing major healthcare innovation is through diagnostics. The time of healthcare professionals in primary care capacities is often taken up by patient intake and initial diagnostics, which can divert a lot of time and energy from effective treatment and patient engagement. AI systems are being developed to take these initial diagnostics out of doctors’ hands; patient symptoms are recorded and interpreted by the AI system, and the patients are automatically referred to the relevant department.

Diagnostic improvements extend from primary care and GP centres to the heart of specialist hospitals and urgent care systems. Similar systems can be used to find unique and unusual patterns in patient symptoms or readings, allowing for a more nuanced investigation of potential causes. In this way, early disease detection is expected to improve dramatically, alongside outcomes for urgent care patients.

Drug Discovery

Speaking of outcomes, AI systems will have a vital role to play in the development of new treatments – particularly the development and discovery of effective drugs. The drug discovery pipeline is necessarily slow and methodical, so as not to unnecessarily endanger life in the trialling of unknown quantities.

The superior computational and modelling power of purpose-built AI systems will enable the quicker and safer synthesis of new potential compounds – and could vastly speed up initial research timelines. Careful trialling and investigation will still be a necessity – as will the legal counsel of life sciences specialists in the coordination of safe and legal drug discovery – but the existence of such intelligent systems could revolutionise the understanding of the chemistry behind initial drug testing.

Medical Imagery

The aforementioned role of AI in diagnostic improvements is a field in and of itself, but there is a tangentially related field of AI development that could further improve patient outcomes concerning the interpretation of data. Many patients require scans to identify issues, be they sources of bleeding, potential tumour presences, or simply broken bones. However, there are elements of human error in the interpretation of scan results, whether visual or data-based.

In training machine learning algorithms on wide data sets of existing MRI or CAT-scan imagery, AI can be developed for the express purpose of reading and interpreting scan information. This could greatly reduce the levels of human error in patient diagnosis and treatment, to say nothing of the additional nuance with which an AI can interpret scan data.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”